吉非替尼联合抗凝方案治疗晚期非小细胞肺癌的疗效研究  

Efficacy of Gefitinib Combined with Anticoagulation for Advanced Non-small Cell Lung Cancer

作　　者：朱九荣 马慧莉 王文廉[1] ZHU Jiurong;MA Huili;WANG Wenlian(Nanyang Central Hospital,Nanyang,473000)

机构地区：[1]河南省南阳市中心医院,473000

出　　处：《实用癌症杂志》2023年第2期270-273,共4页The Practical Journal of Cancer

摘　　要：目的探讨吉非替尼联合抗凝方案治疗晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)的疗效。方法收集晚期NSCLC患者70例,根据单双号分组,即对照组、治疗组,均35例。对照组采用传统化疗方案,治疗组在对照组的基础上采用吉非替尼联合抗凝方案。对比2组疗效。结果治疗组患者临床总有效率为94.29%、疾病控制率为82.86%,均显著高于对照组(χ^(2)=7.652,P=0.006;χ^(2)=9.130,P=0.003)。治疗组血清肿瘤标志物CYFRA21-Ⅰ[(2.21±0.43)ng/ml]、CEA[(5.61±0.72)ng/ml]、SCC[(13.22±1.47)μg/ml]、NSE[(12.48±1.51)μg/L]水平均显著低于对照组(P<0.05)。治疗组不良反应发生率均显著低于对照组(P<0.05)。治疗组KPS评分为(80.31±6.21)分,显著高于对照组(P<0.05)。治疗组FIB[(3.66±1.26)g/L]显著低于对照组,TT[(18.19±1.14)s]显著高于对照组,P<0.05;但2组PT、APTT比较,差异无统计学意义(P>0.05)。结论吉非替尼靶向治疗晚期非小细胞肺癌,可有效促进血清肿瘤标志物水平恢复至正常水平,改善近期疗效和生活质量,安全性高,且吉非替尼联合抗凝方案,可有效改善患者凝血功能,降低静脉血栓形成风险。Objective To investigate the efficacy of gefitinib combined with anticoagulation in the treatment of advanced non-small cell lung cancer(NSCLC).Methods A total of 70 patients with advanced NSCLC were collected and divided into the control group and the treatment group(35 cases).The control group was treated with traditional chemotherapy,and the treatment group was treated with gefitinib combined with anticoagulation.The efficacy of the 2 groups was compared.Results The total effective rate and disease control rate of the treatment group were 94.29%and 82.86%,respectively,which were significantly higher than those of the control group(χ^(2)=7.652,P=0.006;χ^(2)=9.130,P=0.003).The levels of serum tumor markers CYFRA21-Ⅰ[(2.21±0.43)ng/ml],CEA[(5.61±0.72)ng/ml],SCC[(13.22±1.47)μg/ml]and NSE[(12.48±1.51)μg/L]in treatment group were significantly lower than those of the control group(P<0.05).The incidence of adverse reactions in treatment group was significantly lower than that of the control group(P<0.05).The KPS score of the treatment group was(80.31±6.21)points,which was significantly higher than that of the control group(P<0.05).The FIB(3.66±1.26)g/L in the treatment group was significantly lower than that in the control group,and the TT[(18.19±1.14)s]was significantly higher than that of the control group,P<0.05,but there was no statistical significance in PT and APTT between the two groups(P>0.05).Conclusion The targeted treatment of gefitinib in advanced non-small cell lung cancer can effectively restore the level of serum tumor markers to normal level,improve the short-term efficacy and quality of life with high safety,and gefitinib combined with anticoagulant regimen can effectively improve the coagulation function of patients and reduce the risk of venous thrombosis.

关 键 词：非小细胞肺癌 晚期 吉非替尼 血清肿瘤标志物 靶向治疗 临床疗效 

分 类 号：R734.2[医药卫生—肿瘤]